Abbott, Eli Lilly, Novartis: Emerging Markets Earnings Round Up (Part 1)
This article was originally published in PharmAsia News
Executive Summary
Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.
You may also be interested in...
With December Approaching, Are More Turkish Price Cuts On The Way?
Turkey has attracted considerable attention in recent years from multinational pharmaceutical companies looking to grow in emerging markets. But the government of the world's 12-largest pharmaceutical market has also enforced steep price cuts on drugs in each of the last two years, both times in December. With December quickly approaching, are a new round of price cuts on the horizon
With December Approaching, Are More Turkish Price Cuts On The Way?
Turkey has attracted considerable attention in recent years from multinational pharmaceutical companies looking to grow in emerging markets. But the government of the world's 12-largest pharmaceutical market has also enforced steep price cuts on drugs in each of the last two years, both times in December. With December quickly approaching, are a new round of price cuts on the horizon
With December Approaching, Are More Turkish Price Cuts On The Way?
The government of the world's 12th-largest pharmaceutical market has enforced steep price cuts on drugs in each of the last two years, both times in December.